Top View
- Opioid Receptor Research Using ALZET Osmotic Pumps
- TIP 40: Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: Treatment Improvement Protocol (TIP) Series 40
- Distinct Effects of Nalmefene on Dopamine Uptake Rates and Kappa Opioid Receptor Activity in the Nucleus Accumbens Following Chronic Intermittent Ethanol Exposure
- House Bill No. 2038
- Guideline for CYP2D6, OPRM1, and COMT Genotype and Select Opioid
- Controlled Substances List (Adopted by Alabama State Board of Health on January 20, 2021, Effective January 20, 2021)
- The Effects of Herkinorin, the First Mu-Selective Ligand from a Salvinorin A-Derived Scaffold, in a Neuroendocrine Biomarker Assay in Nonhuman Primates
- Efficacy of Ketamine in the Treatment of Substance Use Disorders
- S21. Opioids.Pdf
- Expand Therapeutic Options for Opioid Addiction and Overdose 1
- Benefits and Risks of Pharmaceutical Opioids
- VIRGINIA MILITARY INSTITUTE Lexington, Virginia
- Ketamine for Depression: What Psychologists Need to Know
- WO 2016/086194 Al June 2016 (02.06.2016) W P O P C T
- United States Patent (19) 11 Patent Number: 4,692,451 Dodman Et Al
- Understanding and Addressing Substance Use Disorders As
- Drug Misuse in Adolescents Presenting to the Emergency Department
- Review Procedural Sedation and Analgesia in Children
- Free PDF Download
- Guidelines for the Psychosocially Assisted Pharmacological Treatment
- Levorphanol Tartrate Tablets Usp, Cii Rx Only
- List of Scheduling Actions, Controlled Substances And
- Emit® Drugs of Abuse Urine Assays Cross-Reactivity List
- Selincro, Nalmefene Dihydrochloride Dihydrate
- House Bill No. 2034
- Reference ID: 4756466
- Introducedcavanaugh,Cavanaugh,Hansen, Bymckinney, 11; J., M., 9; 6; M.,Wishart, 26; Morfeld, 27
- Strategies for Developing Kappa Opioid Receptor Agonists for the Treatment of Pain with Fewer Side-Effects
- United States Patent (19) 11 Patent Number: 5,922,705 Simon (45) Date of Patent: Jul
- FDA Advisory Committee on the Most Appropriate Dose Or Doses of Naloxone to Reverse the Effects of Life-Threatening Opioid Overdose in the Community Settings
- Procedural Sedation Overview
- Neurobiology and Principles of Addiction and Tolerance
- Substance-Related Disorders in Adults
- Opiant Pharmaceuticals, Inc. (OPNT-NASDAQ)
- Transdemal Delivery of Opioid Antagonist Prodrugs Audra L
- Salvinorin A, a Kappa-Opioid Receptor Agonist Hallucinogen: Pharmacology and Potential Template for Novel Pharmacotherapeutic Agents in Neuropsychiatric Disorders
- Implantable Technology for Long-Term Delivery of Nalmefene for Treatment of Alcoholism
- (POC) Trial of Ketamine Therapy in Treatment-Resistant Depression
- Guidelines for the Identification and Management of Substance Use and Substance Use Disorders in Pregnancy WHO Library Cataloguing-In-Publication Data
- Investigations of Salvinorin A: Synthetic Isolation, Quantification, and in Vivo Characteristics
- Nalemefene Pathway & Prescribing Guidance
- The Committee on Federal and State Affairs
- Opioid A4: Antidotes in Depth
- Harms Associated with Use of Nalmefene for Substance Use and Impulse Control Disorders
- Opiant Investor Deck Non Confidential Mar 2019
- Antagonists of Excitatory Opioid Receptor Functions Enhance Morphine's Analgesic Potency and Attenuate Opioid Tolerance/Dependence Liability
- Noribogaine Is a G-Protein Biased Κ-Opioid
- Butelman Et Al., 2009) As Well As Discrimina- a Current Or Past History of Psychiatric Disorders, Alcohol Or Tive Stimulus Effects (Butelman Et Al., 2010)
- Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose
- Drug Enforcement Administration, Justice § 1308.12
- TIP 45 Detoxification and Substance Abuse Treatment
- Development of Intranasal Nalmefene to Treat Synthetic Opioid Overdose
- Problems of Drug Dependence, 1993: Proceedings of the 55Th Annual Scientific Meeting the College on Problems of Drug Dependence, Inc
- Australian Public Assessment Report for Nalmefene (As Hydrochloride Dihydrate)
- Behavioural Pharmacology of Novel Kappa Opioid Compounds
- Therapeutic Potentials of Ketamine and Esketamine In
- S(+)-Ketamine Attenuates Increase in Electroencephalograph Activity And
- Legislative Bill 1221
- Psychotropic & Non-Drugs Interactions